Calza Leonardo, D'Antuono Antonietta, Marinacci Ginevra, Manfredi Roberto, Colangeli Vincenzo, Passarini Beatrice, Orioli Roberto, Varoli Ornella, Chiodo Francesco
Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Bologna, St Orsola Hospital, via G. Massarenti 11, I-40138 Bologna, Italy.
J Am Acad Dermatol. 2004 Mar;50(3):461-5. doi: 10.1016/j.jaad.2003.10.005.
Leishmaniasis is emerging as a common and serious opportunistic disease for patients with HIV infection. Almost all cases of HIV-Leishmania coinfection have been described in Mediterranean countries and they occur with various clinical presentations, ranging from typical visceral forms to asymptomatic or atypical cases, including cutaneous and mucocutaneous leishmaniasis. Pentavalent antimony compounds have been the mainstays of antileishmanial therapy for half a century and new lipid formulations of amphotericin B seem reliable, but the most effective treatment remains unknown. We describe a patient who was HIV infected and an intravenous drug user, with an unusual disseminated cutaneous leishmaniasis, after an initial visceral disease and after a 13-month maintenance treatment with liposomal amphotericin. The severe concurrent immunosuppression probably played an essential role in leading to this atypical cutaneous form, characterized by diffuse, nonulcerated, nonscabby maculopapular lesions.
利什曼病正成为HIV感染患者中一种常见且严重的机会性疾病。几乎所有HIV-利什曼原虫合并感染病例均在地中海国家被报道,其临床表现多样,从典型的内脏型到无症状或非典型病例,包括皮肤和黏膜皮肤利什曼病。半个世纪以来,五价锑化合物一直是抗利什曼病治疗的主要药物,新型两性霉素B脂质制剂似乎可靠,但最有效的治疗方法仍不明确。我们描述了一名HIV感染且为静脉吸毒者的患者,在最初出现内脏疾病并接受脂质体两性霉素13个月的维持治疗后,发生了一种不寻常的播散性皮肤利什曼病。严重的并发免疫抑制可能在导致这种以弥漫性、非溃疡性、非结痂性斑丘疹病变为特征的非典型皮肤形式中起了重要作用。